PRESS-RELEASE filed Jul 27, 2026 at 06:04 ET
The Ensign Group reported Q2 2026 GAAP diluted EPS of $1.68 (up 16.7% YoY) and adjusted EPS of $1.92 (up 20.8% YoY), with total revenue of $1.44B (+17.3% YoY). The company raised its full-year 2026 EPS guidance to $7.75-$7.85 and revenue guidance to $5.87B-$5.92B, reflecting strong operational momentum driven by occupancy gains, skilled mix improvement, and disciplined acquisition growth. The beat was modest vs consensus ($1.85 EPS on $1.44B revenue), but the guidance raise and robust clinical/operating metrics support a bullish outlook.